10x Genomics ( (TXG) ) just unveiled an announcement.
On May 6, 2025, 10x Genomics announced a reduction in its global workforce by approximately 8% to decrease costs and align with strategic priorities, estimating related expenses between $5.5 million and $6.5 million. The company reported first-quarter 2025 revenue of $154.9 million, a 10% increase from the previous year, driven by a patent litigation settlement. Despite a decrease in instrument revenue, 10x Genomics plans to reduce operating expenses by over $50 million in 2025 and has unveiled new product launches and a partnership with Arc Institute to enhance its market position.
Spark’s Take on TXG Stock
According to Spark, TipRanks’ AI Analyst, TXG is a Neutral.
10x Genomics is currently facing several challenges, including profitability issues and declining revenue, which significantly impact its financial performance. While the company has a strong equity position and is making strides in product innovation, bearish technical indicators and valuation concerns weigh heavily. The mixed sentiment from the earnings call adds further uncertainty, leading to an overall cautious outlook for the stock.
To see Spark’s full report on TXG stock, click here.
More about 10x Genomics
10x Genomics is a life science technology company specializing in single cell and spatial biology products. Their integrated solutions, including instruments, consumables, and software, aid academic and translational researchers and biopharmaceutical companies in understanding complex biological systems. These products have contributed to advancements in fields such as oncology, immunology, and neuroscience.
Average Trading Volume: 3,597,119
Technical Sentiment Signal: Sell
Current Market Cap: $997.4M
For detailed information about TXG stock, go to TipRanks’ Stock Analysis page.